SS&C Sells the Back Office Regulators Will Not Let Funds Rebuild

Summary and thesis

SS&C Technologies is a roll-up of mission-critical financial and healthcare back-office software and outsourced operations. Asset managers, wealth firms, insurers and health plans run books, investor records and claims on its platforms, and many outsource the work itself to SS&C staff.

Switching means re-papering regulated processes, re-reconciling years of history and convincing auditors and regulators, which is why average revenue retention has stayed above 95% for five years.

The thesis is that superintelligence raises the value of owning the regulated system of record more than it threatens it. Agents can automate reconciliation and investor-statement tasks, but they need audited data, controls and liability-bearing operators underneath, and SS&C provides all three.

The risk side is real: the Blue Prism automation unit is shrinking, and labour-heavy fund administration could be re-priced if operations work becomes cheap. At the Oct 23, 2026 close the market implies only 5.67% annual owner-cash growth for a decade, against 5.2% organic growth in Q3 plus margin expansion and buybacks, and the stock sits about 13.7% below a base value built on the lowest multiple of a nine-year band.

The leverage is high on an owner-cash basis, and founder succession is undisclosed.

Business model and products

Products. Fund administration and outsourcing (GlobeOp) for alternative and traditional managers; GIDS, a global transfer agency and investor servicing platform across the US, Canada, UK, Ireland, Luxembourg, Australia, Hong Kong and Singapore; investment management software including Advent and Eze; wealth platforms; loan and banking software; Intralinks virtual data rooms for deals and investor communications; Blue Prism intelligent and robotic process automation, now including agentic tools; and healthcare pharmacy and medical claims processing. In October 2025 SS&C closed Calastone, a funds transaction network, for $1,031.4M net.

Customers. More than 23,000 clients in financial services and healthcare. In FY2025, 67% of revenue came from the US and 33% internationally.

A breakdown by client type is not disclosed.

Pricing and revenue model. FY2025 revenue was $5,211.1M of software-enabled services (83%, up 7.7%) and $1,061.1M of licence, maintenance and related revenue (17%, up 1.9%). Services are priced on assets under management, accounts serviced, transaction volumes and claim counts, so revenue rises with client assets and activity.

Maintenance fees generally rise annually with the consumer price index. Services contracts run one to five years, are billed monthly or quarterly and usually renew automatically.

Retention and backlog. Average revenue retention exceeded 95% in each of the last five years across services, maintenance and term licences for core enterprise products. Net revenue retention and remaining performance obligations for services are not disclosed.

Concentration. The largest client was under 5% of FY2025 revenue.

Go-to-market. A direct sales force cross-sells acquired products into a large installed base; acquisitions add products and clients that are then integrated.

Competitors. In fund administration, custodian banks (State Street, BNY Mellon, Northern Trust) and Citco; in wealth, Envestnet, Orion, Addepar, SEI and custodians such as Schwab, Fidelity and Raymond James; in loan servicing, PNC (Midland) and McCracken; in data rooms, Datasite and Donnelley Financial; and in-house systems at large firms.

Financials

Organic growth by unit in Q3 2026 shows where the franchise is strongest: GlobeOp fund administration grew 9.0%, GIDS transfer agency 6.3%, Intralinks 6.3%, Wealth and Investment Technologies 1.9%, and Intelligent Automation and Analytics, which includes Blue Prism, fell 4.5%. Acquisitions added about $39M of Q3 revenue.

The dividend was raised 11.1% to $1.20 a year in August. The Q4 outlook implies organic growth of about 4%, below consensus, and the stock fell from $89.54 to $82.96 on Oct 23, 2026, a 7.35% drop.

The Q3 Form 10-Q had not been filed at the time of writing, so balance sheet detail beyond the release is from the Q3 8-K exhibit.

Valuation

Owner cash is operating cash flow less any deferred-revenue build, capex, capitalised software, stock pay and interest income. Over the trailing twelve months to Sep 30, 2026: operating cash flow $1,859.8M, no deferred-revenue build to strip (a $16.3M release), $47.5M of capex, $256.6M of capitalised software, $270.6M of stock pay and $8.4M of interest income, for an anchor of $1,276.7M.

The FY2025 interest figure is used because quarterly interest income is netted inside interest expense; it is under 1% of the anchor. The 2025 tax law change on research expensing was described as immaterial to the 2025 provision, and no catch-up is visible in cash flow, so no strip is applied; this remains provisional until the FY2026 10-K.

Net debt is $6,924.1M (carrying-value debt of $7,449.5M less $525.4M of cash), excluding $3.8B of client-fund cash and matching obligations. At $82.96 and 240.6M diluted shares, enterprise value is about $26.88B, or 21.06x the anchor.

Owner cash has been positive in all nine years from FY2017 to FY2025, and the year-end multiple band ranged from 23.2x (FY2021) to 44.5x. Applying the 23.2x low gives a base value of $94.33, 13.7% above the price.

Capital allocation is the other lever. SS&C has historically alternated between large acquisitions financed with debt and periods of deleveraging, buybacks and dividend growth.

In the last 24 months it closed Calastone ($1,031.4M net), Curo Fund Services (about $16M) and FPS Trust (about $6M), after $645.6M of 2024 deals. Q3 2026 split free cash between $154.8M of buybacks, $70.5M of dividends and $130.0M of debt paydown.

Because diluted shares are guided at 240.0M to 243.0M for Q4, buybacks are roughly offsetting stock-pay dilution rather than shrinking the count materially. A return to large debt-funded deals before leverage falls would weaken the per-share case; continued paydown alongside buybacks would strengthen it.

Moat, control and succession

The moat combines systems of record with regulated workflows. Fund administrators calculate net asset values, maintain investor registers and support audits under multiple regulators; a change of administrator is a multi-quarter project with operational and reputational risk for the fund.

That is why GlobeOp can grow 9% organically while software licence lines grow slowly. Blue Prism is the weak point: generic agent platforms compete directly with robotic process automation, and the unit is shrinking.

SS&C is building agent studios and native MCP servers into Blue Prism WorkHQ, while the core fund-admin and Advent and Eze platforms expose REST integrations without native MCP. Holding margin near 40% while organic growth stays above 4% is the test of the defence.

The founder has been Chairman and CEO since 1986 and owns 14.6% of the stock, the largest holder ahead of BlackRock at 11.6%. A stockholders agreement gives him two board nominations while he holds above 15% and one below that level.

There is one share class, so this is influence without voting control. No succession plan is disclosed.

The President and COO is a plausible internal candidate, but nothing in the filings names a successor, and a founder-led roll-up depends heavily on its deal-maker.

Catalysts and risks

The Q4 2026 print is expected in early February 2027; the date is not confirmed by the company. Points to watch: Q4 organic growth against roughly 4%, the 2027 outlook, the coupon on the refinanced 2027 notes, the Blue Prism trend and the split of cash between buybacks and debt paydown.

Risks are re-pricing of labour-heavy operations work, further automation losses, refinancing costs, acquisition integration and key-person risk.

Key metrics